deltatrials
Completed PHASE3 NCT00034892

CAFE Comparison of Atypicals in First Episode of Psychosis

Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison

Sponsor: AstraZeneca

Conditions Mental Disorders Mental Health Psychotic Disorders Schizophrenia
Interventions Olanzapine, risperidone
Updated 6 times since 2017 Last updated: Jan 3, 2013 Started: Mar 31, 2002 Primary completion: Mar 31, 2005 Completion: Mar 31, 2005

Listed as NCT00034892, this PHASE3 trial focuses on Mental Disorders and Mental Health and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2002, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • University of North Carolina
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Augusta, United States, Boston, United States, Brooklyn, United States, Butner, United States, Calgary, Canada, Chapel Hill, United States, Charlotte, United States, Chicago, United States, Cincinnati, United States and 16 more location s